Sterling Pharmaceuticals Expands: New State-of-the-Art Headquarters in Birmingham
Sterling Pharmaceuticals is pleased to announce the acquisition of land at St. Modwen’s Longbridge Business Park, where we will build a striking new 40,000 sq ft headquarters. This state-of-the-art facility, designed by Birmingham-based architects Glancy Nicholls, marks a significant milestone in the growth of Sterling Pharmaceuticals, an innovative Contract Research Development and Manufacturing Organisation (CRDMO) specialising in the production of non-sterile oral liquids and solid dosage forms, including bespoke ‘unlicensed’ medicines under our ‘Sterling Specials’ brand.
Having outgrown our current research, development, and manufacturing facilities in Moseley, Birmingham, we are excited to expand to Longbridge Business Park. The new facility will enable us to scale up production and continue developing high-quality pharmaceutical products, ensuring that we meet the needs of healthcare providers both in the UK and internationally.
This move to Longbridge is part of our strategic plan to support Sterling’s rapid growth and prepare for the next phase of our business. With the support of Kenny Allan from KWB and David MacMullen of MacMullen Associates, we have secured a prime site within a growing hub known for its focus on science, technology, medicine, and precision engineering.
Image © Irina Mackie. Sterling Pharmaceuticals coming to Longbridge
Your Content Goes Here
The new headquarters will significantly increase our capacity to manufacture and distribute pharmaceuticals, enabling us to expand our workforce to approximately 150 highly skilled professionals. This expansion reinforces our commitment to reshoring pharmaceutical manufacturing to the UK, creating new opportunities for local talent and advancing our collaboration with academic partners, such as Aston University.
“We are delighted with the expertise of KWB and MacMullen Associates in securing this site during a challenging market. Their efforts will allow us to establish a cutting-edge facility that supports the next exciting phase of our growth. We look forward to submitting a planning application after Christmas, with construction due to start in late 2024.” said Dr Qamar Nawaz, Chief Executive Officer at Sterling Pharmaceuticals.
As we enter this new chapter, Sterling Pharmaceuticals remains committed to delivering innovative pharmaceutical solutions that positively impact patient care both locally and globally.
